FIBROSIS IS A HALLMARK OF MULTIPLE DISEASES ACROSS MULTIPLE ORGAN SYSTEMS AS WELL AS DIFFERENT TUMOR TYPES
Alentis is a clinical-stage company building on the discovery that CLDN1 is a novel, previously unexplored target with a unique mechanism of action in the pathology of fibrosis and solid tumors. Moreover, Alentis is building on a unique platform that models the clinical cell circuits of fibrosis progression and cancer in state-of-the-art human cell-based systems. This platform is combined with single-cell RNASeq of patient tissues having uncovered drug candidates in collaboration with the University of Strasbourg and Inserm, the Mount Sinai Hospital, and University of Texas Southwestern (UTSW). Using this cutting-edge platform based on clinically relevant read-outs and patient tissues, Alentis is discovering new targets and developing new medicines to treat fibrosis and solid tumors – key unmet medical needs rising worldwide.
Alentis is using its portfolio of unique anti-CLDN1 monoclonal antibodies (mAbs) that bind to CLDN1 exposed outside of the tight junction to develop a pipeline of novel mechanisms targeting advanced fibrosis.
- ALE.F02, CLDN1 mAb for Liver (F3/F4), kidney, and lung fibrosis, with selected effector function
- ALE.C04, CLDN1 mAb for solid tumors, with an effector function directly targeting cancer while retaining the anti-fibrotic effect (dual effect)
Alentis is widening its therapeutic reach to explore the potential of targeting CLDN1 in fibrosis of other tissues where CLDN1 dysregulation is an established driver of the disease.
Moreover, Alentis’ proprietary discovery cPLS platform (Cellular Prognostic Liver Signature) allows the identification of new targets and supports the fast development of new compounds, which are relevant in fibrosis and solid tumors. We are using our drug discovery platform for pipeline expansion, pioneering a new approach for screening, and the identification of novel targets, biomarkers, and clinical candidates for fibrotic diseases and associated cancers.